Literature DB >> 33261292

Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.

C Perisano1,2, R Vitiello1,2, A Sgambato1,2, T Greco1,2, L Cianni1,2, G Ragonesi2, T Malara3, G Maccauro1,2, M Martini1.   

Abstract

Sarcomas are a heterogeneous group of rare tumours. Improvements in immunotherapy and the important role of PD1 and PD-L1 expression in advancement and prognosis have opened new fields of research for the treatment of these neoplasia. We evaluated the immunohistochemistry of PD1 and PD-L1 expression in 60 adults' patients affected by high-grade sarcomas of the limbs. PD1 expression was 65% while PD-L1 was 68.3%. PD-L1 expression seems to correlate to Ki67 in liposarcomas, fibrosarcoma's and pleomorphic sarcomas, while it does not show any correlation to chondrosarcomas, while in rhabdomyosarcomas there is a correlation but, given the small sample size, it was not possible to perform a statistic analysis. Our study shows positivity among the different subgroups of positive PD1 lymphocytes infiltration and PD-L1 expression in high-grade sarcomas of the limbs. Copyright 2020 Biolife Sas. www.biolifesas.org.

Entities:  

Keywords:  PD; PD-L1; immunotherapy; programmed cell death receptor; sarcoma

Year:  2020        PMID: 33261292

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  2 in total

1.  Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy.

Authors:  Jiayong Liu; Peijie Liu; Fuyu Gong; Youhui Tian; Xiaochen Zhao
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

2.  The role of soluble CD80 in patients with soft tissue tumors.

Authors:  Yumi Matsuyama; Kunihiro Asanuma; Keisuke Yoshida; Tomohito Hagi; Takahiro Iino; Tomoki Nakamura; Akihiro Sudo
Journal:  J Orthop Surg Res       Date:  2022-09-05       Impact factor: 2.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.